Orchestra BioMed

Terumo Corporation has secured exclusive global development and commercialization rights to Virtue sirolimus-eluting balloon (SEB) from Orchestra BioMed, with an upfront payment of $30 million and an equity commitment of $5 million.

Terumo Corporation has secured exclusive global development and commercialization rights to the Virtue Sirolimus-Eluting Balloon by entering into a strategic partnership with Orchestra BioMed. Terumo will make a $30 million upfront payment and a $5 million equity commitment.